# Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/safety-tolerability-cannabidiol-parkinson-disease/ > **Published:** 2021-11-16T15:44:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:02:15-04:00 > **Clinical Summary:** Explore the safety and tolerability of cannabidiol in Parkinson disease patients through an open-label dose-escalation study with preliminary findings. --- Parkinson disease (PD) is a [neurodegenerative disorder](https://cedclinic.com/car-t-cell-therapy-alzheimers-targeting-amyloid-plaques/) very common among the older population. Since standard treatments often only partially relieve symptoms, many patients turn to complementary and alternative medication such as cannabis. However, what are the real risks and benefits of cannabis for Parkinson disease patients? A study investigating the safety and tolerability of a range of doses of cannabidiol (CBD) and its effect on common parkinsonian symptoms conducted by a group of physicians at the University of Colorado School of Medicine provided the first glimpse into this topic. The study focused on CBD – a non-intoxicating, well-tolerated cannabinoid constituent of the cannabis plant and utilized Epidiolex – a FDA approved medication with plant-derived highly purified CBD. Its data indicated that all participants reported [adverse events](https://cedclinic.com/cbd-endocrine-effects-gynecomastia-risk-safety/) during a period of approximately 1 month on this medication. These most often included diarrhea, drowsiness, fatigue, weight gain, dizziness, abdominal pain, headache, weight loss, nausea, anorexia, and increased appetite. [Adverse events](https://cedclinic.com/cbd-endocrine-effects-gynecomastia-risk-safety/) were mostly mild; none serious. Abnormally high liver enzymes also occurred in 38.5% participants on high dose. Among participants that completed the study, all exhibited improvement in total and motor scores in the Movement Disorder Society Unified Parkinson Disease Rating Scale. In addition, nighttime sleep and emotional/behavioral dyscontrol scores improved significantly. Based on these findings, the physicians concluded that CBD, in the form of Epidiolex, may be efficacious in PD, but at a relatively high dose was associated with liver enzyme elevations. However, as an open-label study with a small sample size, this study only offered preliminary insights. Future randomized controlled trials to investigate various forms of cannabis in PD, therefore, are urgently needed. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Topical Cannabis for AIMSS: Cannabinoid Clinical Trial](https://cedclinic.com/topical-cannabis-aromatase-inhibitor-joint-pain-trial/) Learn about [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) exploring topical cannabis treatments for AIMSS symptoms and their safety profiles. [Read More](https://cedclinic.com/topical-cannabis-aromatase-inhibitor-joint-pain-trial/) [Cannabis Derivatives & Autism Spectrum Disorder: Evidence from Clinical Research](https://cedclinic.com/cannabis-derivatives-autism-spectrum-disorder-evidence/) Explore [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on cannabis derivatives and their potential therapeutic effects in autism spectrum disorder. [Explore Research](https://cedclinic.com/cannabis-derivatives-autism-spectrum-disorder-evidence/) [Cannabinoids for Autism: Clinical Evidence Reviewed](https://cedclinic.com/therapeutic-cannabis-autism-systematic-review/) A comprehensive review of [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) on cannabinoids used in autism treatment and their safety considerations. [Learn More](https://cedclinic.com/therapeutic-cannabis-autism-systematic-review/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Safety%20and%20Tolerability%20of%20Cannabidiol%20in%20Parkinson%20Disease%3A%20An%20Open%20Label%2C%20Dose-Escalation%20Study&url=https%3A%2F%2Fcedclinic.com%2Fsafety-tolerability-cannabidiol-parkinson-disease%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fsafety-tolerability-cannabidiol-parkinson-disease%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Safety%20and%20Tolerability%20of%20Cannabidiol%20in%20Parkinson%20Disease%3A%20An%20Open%20Label%2C%20Dose-Escalation%20Study%20https%3A%2F%2Fcedclinic.com%2Fsafety-tolerability-cannabidiol-parkinson-disease%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).